Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have been given an average rating of “Buy” by the eight brokerages that are presently covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $10.57.

Several research firms have commented on AQST. Raymond James set a $7.00 target price on shares of Aquestive Therapeutics in a report on Friday, March 7th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research report on Wednesday. Cantor Fitzgerald assumed coverage on shares of Aquestive Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $17.00 price objective for the company. Lake Street Capital reduced their target price on Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, March 7th. Finally, Alliance Global Partners reaffirmed a “buy” rating on shares of Aquestive Therapeutics in a report on Friday, March 7th.

Institutional Trading of Aquestive Therapeutics

A number of hedge funds have recently added to or reduced their stakes in AQST. New York State Common Retirement Fund lifted its stake in shares of Aquestive Therapeutics by 713.3% in the 4th quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock valued at $43,000 after acquiring an additional 10,700 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Aquestive Therapeutics during the 4th quarter worth $44,000. Two Sigma Advisers LP acquired a new position in Aquestive Therapeutics in the 4th quarter worth about $57,000. PKS Advisory Services LLC bought a new position in Aquestive Therapeutics in the fourth quarter valued at about $63,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Aquestive Therapeutics during the third quarter valued at about $90,000. Institutional investors and hedge funds own 32.45% of the company’s stock.

Aquestive Therapeutics Trading Down 5.6 %

NASDAQ AQST opened at $2.71 on Monday. The company has a market cap of $267.94 million, a price-to-earnings ratio of -6.02 and a beta of 2.59. The company has a 50 day moving average of $2.97 and a 200-day moving average of $3.89. Aquestive Therapeutics has a 1-year low of $2.24 and a 1-year high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The business had revenue of $11.87 million during the quarter, compared to analysts’ expectations of $13.11 million. On average, equities research analysts forecast that Aquestive Therapeutics will post -0.46 earnings per share for the current year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.